- India restrict Pakistan to 105-8 in Women's T20 World Cup
- England target repeat of Pakistan Test whitewash
- Penrith Panthers win fourth straight NRL title after downing Storm
- Weary Sinner happy for day off after battling into Shanghai last 16
- Pakistan's Masood warns England still a force without Stokes
- Madrid's Carvajal to miss several months after serious knee injury
- Israel pounds Lebanon ahead of Hamas attack anniversary
- Two elephants die in flash flooding in northern Thailand
- Sabalenka targets world number one and Wuhan hat-trick
- Toddler among 4 dead in migrant Channel crossings
- Tunisia votes with Saied set for re-election
- Bagnaia sets 'example' with Japan MotoGP win to cut gap on Martin
- Intense Israeli bombing rocks Beirut ahead of war anniversary
- Mozambique vote: no suspense but some disillusion
- Austrian rapper channels anti-racist rage in Romani hip-hop songs
- Ohtani magic powers Dodgers over Padres in MLB playoff thriller
- Five of the best: Pakistan-England Test thrillers
- Man sets arm on fire as marches across US mark Gaza war anniversary
- Vietnam's young coffee entrepreneurs brew up a revolution
- Trump rallies at site of failed assassination: 'Never quit'
- Too hot by day, Dubai's floodlit beaches are packed at night
- Is music finally reckoning with #MeToo?
- Fans hail Trump's 'guts' as he returns to site of rally shooting
- Lebanon state media says 'very violent' Israeli strikes hit south Beirut
- Guardians maul Tigers, miracle Mets rally in MLB series openers
- Lebanon state media says Israeli strikes hit south Beirut
- Miami on track for MLS record points after win in Toronto
- Madrid beat Villarreal but Carvajal suffers knee injury
- Madrid beat Villarreal to move level with Liga leaders Barcelona
- Monaco take top spot in Ligue 1 with win at Rennes
- French rugby player on rape charge whistled but 'serene' on return
- Madrid beat Villarreal to level Liga leaders Barca
- Thuram treble fires Inter past Torino and up to second
- 'Fight': defiant Trump jets in to site of rally shooting
- Toddler among 3 dead in migrant Channel crossings
- Mexico City's new mayor sworn in with pledges on water, housing
- Israel on alert ahead of Hamas attack anniversary
- Guardians maul Tigers in MLB playoff series opener
- Macron criticises Israel on Gaza, Lebanon operations
- French rugby player whistled but 'serene' on return amid ongoing rape case
- Kovacic stars as Man City sink Fulham to get title bid back on track
- Retegui hat-trick fires five-star Atalanta to hammering of Genoa
- Heavyweights Australia, England off to World Cup winning starts
- Visiting UN refugee agency chief decries 'terrible crisis' in Lebanon
- Spinners come to party as England defeat Bangladesh at T20 World Cup
- Search continues for missing in deadly Bosnia floods
- Man City sink Fulham to get title bid back on track
- France's Auradou whistled on Pau return in Perpignan loss amid ongoing rape case
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Arsenal hit back in style after Southampton scare
Astra warns on falling Covid treatment sales after record year
British Covid vaccine maker AstraZeneca on Thursday warned that coronavirus product sales and profit margins would drop this year as the pandemic recedes and after record-high group revenue in 2021.
AstraZeneca rapidly developed a successful Covid-19 jab during the pandemic that generated full-year sales of almost $4.0 billion (3.5 billion euros) last year, the company said in a results statement.
After initially offering the vaccine at cost, Astra decided in November to begin selling Vaxzevria -- developed alongside University of Oxford -- for profit.
- Covid revenue decline -
Revenue from Covid-19 medicines is set to decline by up to a quarter, AstraZeneca said Thursday.
But total group revenues would increase this year by a "high-teens percentage" thanks in part to sales of antibody treatment Evusheld.
The drug is for high-risk people who show resistance to vaccines against coronavirus.
Astra on Thursday added that its net profit tumbled last year, hit by costs arising from the vast takeover of US biotech firm Alexion.
Profit after tax slumped to $112 million (98 million euros) from $3.2 billion in 2020.
Revenues soared 41 percent to $37.4 billion.
"2021 was an exceptional year for AstraZeneca in terms of revenue, which exceeded $37 billion and was the highest in the company's history," noted chief executive Pascal Soriot.
"This put us well on track to deliver our promise of annual revenue of $40 billion one year ahead of schedule."
He added that AstraZeneca's "rapidly improving financial position" had allowed it to raise its annual dividend payment the first time in a decade.
Soriot said the company last year delivered on its "promise of broad and equitable access" to its Covid-19 vaccine" with 2.5 billion doses released for supply around the world".
At the same time, the group faced vast costs following its $39-billion takeover of Alexion, while large impairment and restructuring charges also weighed.
Astra swung into a pre-tax annual loss of $265 million, after a $3.9-billion profit last time around.
But its share price was up 2.1 percent in London trading Thursday.
"The Covid vaccine has raised Astra's global profile significantly," said Hargreaves Lansdown analyst Keith Bowman.
"For now, and with further innovation and new drug successes ongoing, analyst consensus opinion continues to point to a strong buy" of its shares.
Since taking the helm at AstraZeneca in 2012, Soriot has pushed the company into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.
As for its Covid vaccine, "time spent developing and distributing (the jab)... has been time away from its core business", Bowman added.
"The purchase of Alexion at what is considered a full price is also yet to be fully justified."
Astra's EU's Covid vaccination roll-out was extremely sluggish initially because of a big shortfall in the amount of doses the company had promised the bloc, sparking a row between the parties.
The European Union has since pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer in partnership with German peer BioNTech, after rare blood-clot problems with AstraZeneca increased public hesitancy about taking it.
P.Stevenson--AMWN